-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Srixon Announces Buy 2, Get 1 Free Golf Ball Promotion
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
-
Who Is the Best Spanish-Speaking Private Investigator in Sacramento?
-
Healixa Turns Patents Into Products: FrostPulse(TM) Delivered and Five Eternal Spring(TM) Units Enter Production
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Cosmos Health Reports Record Nine-Month Revenue of $53.6 Million, Up 18%; Q3 Gross Margin Up 465 Basis Points Sequentially; Total Debt Down 34% and Stockholders' Equity Up 21% Since Year-End
-
Nearly Half of Transformation Initiatives Face a 'Momentum Gap' That Puts Value at Risk, NSP & Company Study Finds
-
CXAI Expands Agentic AI Reach into Mid-Market Through EngineRoom's Simpro Partnership
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Agency Guacamole's 10th B.L.N.D. Event Brought Industry Leaders Together for a Conversation on the Evolution of Diversity and Inclusion in Beauty
-
From Pilot to Production: InHand Networks' Practical Approach to Industrial Edge AI
Senegal-made sickle cell treatment raises hopes, reduces costs
Mamadou Tahirou is 18 but looks more like a 12-year-old, his frame frail from the ravages of sickle cell disease, which one Senegalese laboratory is hoping to attenuate with affordable drug production.
The lab is producing generic hydroxyurea, the gold standard in sickle cell treatment, for the first time ever in Africa.
Speaking to AFP from his family home near Dakar, Tahirou, eyes bulging and features marked by fatigue, described a life dictated by the hereditary disease, which affects nearly eight million people worldwide.
Bone pain, severe anaemia, extreme fatigue and intense headaches: these symptoms frequently land him in the hospital, Tahirou said, while his 40-year-old mother, Rabiatou, watched helplessly nearby, her eyes swelling with tears.
Fits of pain sometimes flare up while he is in class, disrupting his education and forcing him to miss school regularly.
Africa accounts for nearly 80 percent of all sickle cell disease cases.
Yet the continent remains largely dependent on expensive medicines imported from Europe and the Americas, especially hydroxyurea, the treatment recommended by the World Health Organization (WHO).
The medication helps reduce painful crises, hospitalisations, the need for blood transfusions and death, according to the organisation.
- Interest across west Africa -
"I was three years old when I was diagnosed with sickle cell disease. I've been living with it ever since", Tahirou told AFP, slumped in the family living room.
Senegalese pharmaceutical firm Teranga Pharma is producing a local treatment it touts as more affordable and better suited to patients' realities.
In November 2025, the company launched Drepaf, available in 500 milligram doses for adults and 100 milligram doses for children, with the goal of "reducing the crisis threefold".
The generic drug offers hope for addressing the shortage of treatments and reducing reliance on more costly imported medication.
And it is already garnering interest from several countries across the continent.
The initiative is backed by 4 billion CFA ($7.1 million) in funding and comes at a time when access to imported treatments has become difficult.
A study published in 2023 in Blood, a medical journal of the American Society of Hematology, reported that 78 percent of healthcare professionals surveyed across 13 French-speaking sub-Saharan African countries cited frequent disruption of supplies of hydroxyurea.
The two versions of Drepaf are sold to pharmacies at a wholesale price of 3,000 and 1,500 CFA respectively.
Hydrea and Siklos, hydroxyurea drugs already on the market, cost up to three times as much.
Teranga Pharma CEO Mouhamadou Sow, himself a pharmacist, said that Drepaf's paediatric version fulfils the critical need for a formula suitable for use from the age of nine months.
He spoke to AFP from the company's 9,000 square-metre (97,000 square-foot) factory in Mbao, on the outskirts of Dakar.
Before Drepaf, if a person was unable to obtain or afford imported medicine, no local solution was available.
"Doctors often had to treat the consequences of the disease rather than addressing its root cause, the red blood cells", he said.
Teranga Pharma is working with an Indian technical partner to ramp up production and supply other African nations.
The laboratory says it is already working with Burkina Faso, Guinea and Ivory Coast, and that it has received requests from the Democratic Republic of Congo, Gabon and Cameroon.
- Step forward -
The company aims to meet demand from the entire sub-Saharan continent by 2030, as part of a strategy to strengthen Africa's pharmaceutical sovereignty.
Drepaf represents a significant step forward in the care of children, said Magueye Ndiaye, president of the Senegalese Association for the Fight Against Sickle Cell Disease (ASD).
"Until now, patients had to buy two boxes of 20 tablets. Now a single box of Drepaf, which contains 60, is enough and for the same price", he said.
Lala Dieng, whose 17-year-old son was diagnosed six years ago, noticed an improvement.
"Doctors used to prescribe Hydrea 500 to alleviate his episodes. He recently switched to Drepaf 100, and I've noticed he has far fewer attacks", she told AFP.
Ndiaye said increased awareness about early screening is also helping, since babies who are treated early fare better, and pre-marital testing can even help couples decide whether they want to move forward and conceive together.
As a genetic carrier of sickle cell disease, he has for 20 years now been sharing his experience and advocating for awareness.
On World Sickle Cell Day on June 19, he brought together specialists to advocate for comprehensive care combining medication and psychosocial support to improve patients' life expectancy.
T.Sanchez--AT